66 Results for "

rat lung

" in MedChemExpress (MCE) Product Catalog:
Products (66)

66 Results for "rat lung" in MCE Product Catalog:

323
323 Publications Verification
Cat. No.: HY-10201
CAS No.: 284461-73-0
Purity:  99.92%
Synonyms: Bay 43-9006
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .
loading...
    loading...
323
323 Publications Verification
Cat. No.: HY-10201A
CAS No.: 475207-59-1
Purity:  99.75%
Synonyms: Bay 43-9006 tosylate
Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P1098
CAS No.: 151988-33-9
Target:  

Annexin A NF-κB

Research Areas:  

Inflammation/Immunology

Ac2-26 is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ameliorates lung ischemia-reperfusion injury. Ac2-26 also inhibits airway inflammation and hyperresponsiveness in an asthma rat model .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P1098A
Target:  

Annexin A NF-κB

Research Areas:  

Inflammation/Immunology

Ac2-26 TFA is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ameliorates lung ischemia-reperfusion injury. Ac2-26 also inhibits airway inflammation and hyperresponsiveness in an asthma rat model .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P1098B
Target:  

IKK

Research Areas:  

Inflammation/Immunology

Ac2-26 ammonium is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 ammonium induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ammonium ameliorates lung ischemia-reperfusion injury. Ac2-26 ammonium also inhibits airway inflammation and hyperresponsiveness in an asthma rat model .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-B0182
CAS No.: 61422-45-5
Synonyms: HCFU
Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N1462
CAS No.: 102130-43-8
Atractyloside potassium salt is a powerful and specific inhibitor of mitochondrial ADP/ATP transport. Atractyloside potassium salt inhibits chloride channels from mitochondrial membranes of rat heart. Atractyloside potassium salt activates autophagy, inhibits ANT2, mTOR and promotes the activation of p-AMPK. Atractyloside potassium salt has anti-cancer effects on non-small cell lung cancer and can inhibit liver steatosis. Atractylodesin potassium salt has nephrotoxicity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-B0735A
CAS No.: 67227-57-0
Synonyms: Fenoldopam methanesulfonate; SKF-82526 mesylate
Fenoldopam (SKF-82526) mesylate is a selective dopamine D1 receptor agonist. Fenoldopam mesylate binds to rat D1B dopamine receptors (Kd = 11 nM) and human D1A receptors (Kd = 17 nM) in COS-7 cell membranes expressing the cloned receptors. Fenoldopam mesylate modulates dopamine receptor expression, induces vasorelaxation in vascular tissues, reverses glomerular hyperfiltration in rat models, increases intracellular cAMP levels, promotes DARPP-32 phosphorylation in small cell lung cancer (SCLC) cells, inhibits cytokine secretion, and downregulates T cell activation markers in activated human T cells. Fenoldopam mesylate can be used for research on hypertension, acute kidney injury, psoriasis, and small cell lung cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-101381
CAS No.: 102394-31-0
Purity:  99.93%
Synonyms: AF-DX 116
Target:  

mAChR

Otenzepad (AF-DX 116) is a selective and competitive M2 muscarinic acetylcholine receptor antagonist, with IC50 values of 640 nM and 386 nM for rabbit peripheral lung and rat heart, respectively .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12119
CAS No.: 210354-22-6
Purity:  ≥98.0%
Target:  

NO Synthase

GW274150 is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 also displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 exerts a protective role in an acute model of lung injury inflammation .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12119A
CAS No.: 438542-15-5
Purity:  99.85%
Target:  

NO Synthase

GW274150 phosphate is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 phosphate displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 phosphate exerts a protective role in an acute model of lung injury inflammation .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10201S
CAS No.: 1130115-44-4
Purity:  98.17%
Synonyms: Donafenib; Bay 43-9006-d3
Sorafenib-d3 (Donafenib) is the deuterated-labeled Sorafenib (HY-10201). Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B1505
CAS No.: 652-37-9
Synonyms: Theophyllineacetic acid; Theophylline-7-acetic acid
Acefylline (Theophyllineacetic acid), a xanthine derivative, is an Adenosine Receptor antagonist. Acefylline is a peptidylarginine deiminase (PAD) activator. Acefylline is also a bronchodilator and cardiac stimulant that inhibits rat lung cAMP phosphodiesterase isoenzymes. Acefylline can be used in asthma research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10201S2
CAS No.: 1210608-86-8
Purity:  98.35%
Synonyms: Bay 43-9006-13C,d3
Sorafenib- 13C,d3 (Bay 43-9006- 13C,d3) is the 13C, deuterated-labeled Sorafenib (HY-10201). Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P73101
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: HGF; Hepatocyte Growth Factor (Hepapoietin A; Scatter Factor); Prev. DFNB39; lung Fibroblast-Derived Mitogen; HPTA; Hepatopoietin-A; SF; Scatter Factor; F-TCF; Deafness, Autosomal Recessive 39; HGFB; Hepatopoietin A; Hepatocyte Growth Factor; Fibroblast-D
Species:  
Rat
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-103193
CAS No.: 138605-00-2
Purity:  99.86%
Synonyms: Colforsin dapropate hydrochloride
Target:  

Adenylate Cyclase

Research Areas:  

Cardiovascular Disease

NKH477 (Colforsin dapropate hydrochloride) directly activates the catalytic unit of adenylate cyclase and increases intracellular cAMP. NKH477 is a forskolin derivative that improves cardiac failure mainly through its beneficial effects on diastolic cardiac function. NKH477 exerts an antiproliferative effect in vivo with an altered cytokine profile to inhibit the acute rejection of rat orthotopic lung allografts .
loading...
    loading...
Cat. No.: HY-P990106

Target:  

VEGFR Apoptosis

Research Areas:  

Cancer

Anti-Mouse VEGFR-2 Antibody (DC101) is a rat anti-mouse VEGFR2 monoclonal antibody. Anti-Mouse VEGFR-2 Antibody (DC101) inhibits tumor angiogenesis by blocking the binding of VEGF and VEGFR2. Anti-Mouse VEGFR-2 Antibody (DC101) promotes immune cell infiltration and induces tumor cell apoptosis. Anti-Mouse VEGFR-2 Antibody (DC101) can be used for researches on various types of cancer such as melanoma, lung cancer and breast cancer .
loading...
    loading...
Cat. No.: HY-148226
CAS No.: 1092380-14-7
Purity:  99.28%
20-5,14-HEDGE is a 20-HETE analog. 20-5,14-HEDGE induces cell death in organotypic hippocampal slice cultures (OHSCs). 20-5,14-HEDGE enhances ROS production and reduces hypoxia-reoxygenation (HR)-induced apoptosis in ex vivo rat lung slices. 20-5,14-HEDGE protects against lung ischemic reperfusion injury in rats. 20-5,14-HEDGE can be used for the study of pulmonary vascular signaling and lung injury-related research .
loading...
    loading...
Cat. No.: HY-124211
CAS No.: 189-55-9
Purity:  ≥98.0%
Dibenzo (a,i) pyrene is a polycyclic aromatic hydrocarbon and also a carcinogenic ligand of the TCDD (Ah) receptor. Dibenzo (a,i) pyrene binds to the TCDD (Ah) receptor in rat liver. Dibenzo (a,i) pyrene induces DNA adduct formation and upregulates the protein levels of p53 and p21 WAF1 in diploid lung fibroblasts. Dibenzo (a,i) pyrene alters the cell cycle distribution of diploid lung fibroblasts, increasing the proportion of cells in the S phase, decreasing the proportions of cells in the G0/G1 and G2/M phases, and causing S phase delay/arrest. Dibenzo (a,i) pyrene is applicable for cancer research .
loading...
    loading...
Cat. No.: HY-116749
CAS No.: 217798-39-5
Purity:  ≥98.0%
Synonyms: BBSKE
Target:  

TrxR

Research Areas:  

Cancer

Ethaselen (BBSKE) is an orally active, selective thioredoxin reductase (TrxR) inhibitor with IC50s of 0.5 and 0.35 μM for the wild-type human TrxR1 and rat TrxR1, respectively. Ethaselen specifically binds to the unique selenocysteine-cysteine redox pair in the C-terminal active site of mammalian TrxR1. Ethaselen, an organoselenium compound, is a potent antitumor candidate that exerts potent inhibition on non-small cell lung cancer (NSCLC) by targeting TrxR .
loading...
    loading...